American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.
In chronic lymphocytic leukemia patients with chronic graft-versus-host disease (cGVHD) following allogeneic stem-cell transplantation, treatment with ibrutinib resulted in clinically meaningful and durable responses in patients who had failed at least 1 prior treatment for cGVHD, with a sustained overall response rate of 71% for ≥20 weeks. Read More ›

Healthcare utilization of chronic lymphocytic leukemia (CLL) patients who remain on bendamustine-rituximab (BR) is significantly lower than patients who remain on fludarabine, cyclophosphamide, and rituximab (FCR). Patients aged ≥70 years receiving FCR experienced significantly more days of hospitalization, outpatient visits, and emergency department visits than patients of the same age treated with BR, suggesting BR as an effective, safe, and value-based treatment option for elderly CLL patients. Read More ›

In a multicenter, retrospective analysis of 683 patients with chronic lymphocytic leukemia (CLL), relative efficacy and optimal sequencing of ibrutinib (Ibr), idelalisib (Ide), and venetoclax (Ven) were evaluated. Using overall response rate and progression-free survival as clinical end points, Ibr appears superior to Ide in all settings as first choice kinase inhibitor (KI). In the setting of KI failure, an alternate KI or Ven therapy appears superior to chemoimmunotherapy, whereas an alternate KI appears particularly effective in the setting of intolerance to a prior KI. The use of Ven upon Ibr failure may be superior to the use of Ide. These data provide guidance for sequencing of novel agents. Read More ›

In the prospective, open-label, multicenter, phase 2 CLL2-BIG trial, induction treatment with obinutuzumab and ibrutinib followed by maintenance therapy with continuous ibrutinib and obinutuzumab in a heterogeneous CLL population resulted in an overall response rate of 100% and an minimal residual disease–negativity rate of 47% in the peripheral blood, with no major toxicity. Read More ›

Obinutuzumab (Gazyva)-based induction and maintenance chemotherapy extended progression-free survival (PFS) compared with standard-of-care rituximab (Ritux­an)-based chemotherapy in patients with untreated follicular lymphoma, said Robert E. Marcus, MBBS, FRCP, FRCPath, King’s College Hospital, London, who presented the results from the phase 3 GALLIUM clinical trial at the 2016 American Society of Hematology meeting. Read More ›

The investigational chimeric antigen receptor (CAR) T-cell therapy KTE-C19 achieved complete responses that were durable for >1 year in more than 75% of patients with aggressive lymphomas who had no other effective treatment options, according to results from the phase 2 pivotal clinical trial ZUMA-1 that were presented by Sattva S. Neelapu, MD, Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center, at the 2016 American Society of Hematology meeting. Read More ›

Treatment of elderly and/or unfit chronic lymphocytic leukemia (CLL) patients with chlorambucil plus rituximab was associated with low toxicity, a high overall response rate, and durable progression-free survival, suggesting that in low-risk unfit patients, this combination may be an optimal therapeutic option taking into consideration safety, efficacy, and cost. Read More ›

Healthcare utilization of elderly chronic lymphocytic leukemia (CLL) patients who remain on bendamustine-rituximab (BR) is significantly lower than patients who remain on fludarabine, cyclophosphamide, and rituximab (FCR), with FCR-treated patients experiencing significantly more days of hospitalization, outpatient visits, and emergency department visits than BR-treated patients. Read More ›

In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Read More ›

Using a novel electronic health record database that included nearly 800 chronic lymphocytic leukemia patients, recent treatment patterns in the United States showed a decline in the use of fludarabine-, bendamustine-, and rituximab-containing regimens and a significant increase in the use of obinutuzumab and ibrutinib, either as monotherapy or in combination regimens. Read More ›

Page 29 of 44

Conference Coverage Proudly Presented by
CONQUER: the patient voice
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications